Bullfrog AI Holdings, Inc. Common Stock (BFRG) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Bullfrog AI Holdings, Inc. Common Stock (BFRG) Healthcare & Pipeline Overview

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical entity, utilizing its proprietary bfLEAP artificial intelligence and machine learning platform to analyze preclinical and clinical data. The company holds licensing agreements for therapeutic candidates, focusing on areas like hepatocellular carcinoma, obesity, and non-alcoholic fatty liver disease, aiming to advance drug discovery and development.

What Is the Investment Thesis for BFRG?

Bullfrog AI Holdings, Inc. is positioned as an early-stage digital biopharmaceutical company leveraging AI/ML to enhance drug discovery and development. The company's primary asset, the bfLEAP platform, offers a data-driven approach to analyzing preclinical and clinical data, which could potentially accelerate therapeutic identification and optimization. Key value drivers include the proprietary nature of the bfLEAP platform and its licensing agreements for promising therapeutic candidates. The agreement with George Washington University for siRNA targeting Beta2-spectrin addresses significant markets like hepatocellular carcinoma, obesity, NAFLD, and NASH, diseases with substantial global prevalence and limited effective treatments. Similarly, the Johns Hopkins University license for a Mebendazole formulation targets various human cancers, a perpetually high-need area. Growth catalysts would primarily stem from successful progression of these licensed assets through preclinical and clinical development stages, demonstrating the bfLEAP platform's efficacy in identifying viable therapeutic pathways. Given the company's current negative profit margin of -5205.9% and a market capitalization of $9.00M, it operates in a high-risk, high-reward segment. The negative Beta of -3.00 suggests a highly uncorrelated or inverse relationship with the broader market, which could indicate specific company-level drivers or early-stage volatility. Future milestones in drug development and platform validation are critical for potential value creation.

Based on FMP financials and quantitative analysis

BFRG Key Highlights

Proprietary bfLEAP AI/ML platform designed for advanced analysis of preclinical and clinical data in medicine and healthcare.

• Strategic licensing agreements for therapeutic candidates, including siRNA targeting Beta2-spectrin for metabolic and liver diseases, and a Mebendazole formulation for cancer.
• Operates with a lean team of 4 employees, focusing on specialized AI/ML and biopharmaceutical development.
• Reported a gross margin of 18.4%, indicating the cost efficiency of its core operations relative to revenue.
• Current market capitalization stands at $9.00M, reflecting its early-stage development and market valuation.

Who Are BFRG's Competitors?

BFRG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BFRG's Key Strengths?

Proprietary bfLEAP AI/ML platform for data analysis in medicine and healthcare.

• Strategic licensing agreements for therapeutic candidates targeting significant disease areas (e.g., liver disease, cancer).
• Focused expertise at the intersection of AI/ML and biopharmaceutical development.
• Lean operational structure allowing for agility in R&D.

What Are BFRG's Weaknesses?

Negative profit margin of -5205.9% indicates significant unprofitability.

• Small employee base (4 employees) may limit scale and breadth of R&D efforts.
• Early-stage company with therapeutic candidates still in preclinical or early development.
• Reliance on external licensing agreements for core therapeutic assets.

What Could Drive BFRG Stock Higher?

BFRG catalyst: Successful progression of siRNA targeting Beta2-spectrin through preclinical studies and into an Investigational New Drug (IND) application for diseases like hepatocellular carcinoma or NAFLD.

• Achievement of key preclinical milestones for the Mebendazole formulation licensed from Johns Hopkins University, demonstrating efficacy in cancer models.
• Continued refinement and expansion of the bfLEAP AI/ML platform's capabilities, leading to enhanced data analysis efficiency and predictive power for new therapeutic targets.
• Formation of new strategic partnerships or collaborations with larger pharmaceutical companies to co-develop or license therapeutic assets.

What Are the Key Risks for BFRG?

Financial-distress signal — its Altman Z-Score of 1.49 sits in the distress zone (elevated bankruptcy risk).

• High capital requirements and significant R&D expenses inherent in biopharmaceutical development, exacerbated by a current negative profit margin of -5205.9%.
• Failure of licensed therapeutic candidates (siRNA targeting Beta2-spectrin or Mebendazole formulation) to demonstrate efficacy or safety in preclinical or future clinical trials.
• Intense competition from established pharmaceutical companies and other AI-driven biotech firms with greater financial resources and broader pipelines.
• Regulatory hurdles and the lengthy, unpredictable nature of drug approval processes, which could delay or prevent market entry for any successful therapies.
• Dependence on the continued efficacy and competitive advantage of its proprietary bfLEAP AI/ML platform in a rapidly evolving technological landscape.

What Are the Growth Opportunities for BFRG?

• Expansion of bfLEAP Platform Applications: The bfLEAP AI/ML platform currently focuses on preclinical and clinical data analysis. A significant growth opportunity lies in expanding its application to other stages of the drug lifecycle, such as target identification, lead optimization, or even post-market surveillance for drug repurposing. The global market for AI in drug discovery and development is projected to grow from approximately $1.1 billion in 2022 to over $10 billion by 2027, indicating substantial room for platform expansion. By demonstrating the platform's versatility and efficacy across a broader range of biopharmaceutical challenges, Bullfrog AI could attract more partnerships and licensing deals, potentially within the next 3-5 years, leveraging its core technological advantage.
• Advancement of Licensed Therapeutic Candidates: Bullfrog AI holds licensing agreements for siRNA targeting Beta2-spectrin and a Mebendazole formulation. The successful progression of these candidates through preclinical studies and into human clinical trials represents a critical growth driver. For instance, the market for NAFLD/NASH treatments alone is estimated to reach over $25 billion by 2027. Achieving key milestones, such as IND (Investigational New Drug) application approvals or positive Phase 1/2 clinical trial results for any of these assets, would significantly validate the company's approach and potentially attract further investment or partnership opportunities within a 2-4 year timeframe.
• Strategic Partnerships and Collaborations: Given its lean operational structure and specialized AI/ML focus, Bullfrog AI has a substantial opportunity to forge strategic partnerships with larger pharmaceutical companies, contract research organizations (CROs), or academic institutions. Such collaborations could provide access to additional funding, extensive R&D resources, broader data sets for platform refinement, and established clinical development expertise. The global pharmaceutical outsourcing market, which includes R&D services, is valued at hundreds of billions of dollars. Securing a major partnership could significantly de-risk its development pipeline and accelerate market access for its technologies and therapeutic candidates, potentially within the next 1-3 years.
• Expansion into New Therapeutic Areas: The current licensing agreements focus on hepatocellular carcinoma, obesity, NAFLD, NASH, and various cancers. Bullfrog AI could leverage its bfLEAP platform to identify and pursue new therapeutic targets or indications where AI/ML can provide a distinct advantage. The platform's ability to analyze diverse data sets makes it adaptable. Exploring areas such as neurodegenerative diseases, rare diseases, or infectious diseases, each representing multi-billion dollar markets, could diversify its pipeline and reduce reliance on a few specific assets. This expansion would likely be a medium-to-long-term strategy, unfolding over 3-7 years, contingent on platform validation and resource availability.
• Intellectual Property Expansion and Monetization: Beyond its current licensing agreements, Bullfrog AI can focus on continually expanding its intellectual property portfolio related to the bfLEAP platform itself, as well as new therapeutic discoveries enabled by it. This could involve filing new patents for algorithms, data analysis methods, or novel drug candidates identified. A robust IP portfolio enhances the company's competitive moat and provides additional avenues for monetization, such as out-licensing the platform technology or specific drug candidates to other biopharmaceutical companies. The value of intellectual property in the biotech sector is immense, with licensing deals often reaching hundreds of millions or even billions of dollars over time. This ongoing strategy would continuously build value over the long term.

What Are BFRG's Competitive Advantages?

• Proprietary bfLEAP AI/ML platform, representing specialized algorithms and data analysis capabilities in biopharma.
• Exclusive licensing agreements with George Washington University and Johns Hopkins University for specific therapeutic candidates.
• Early-mover advantage in applying AI/ML to specific therapeutic areas, potentially leading to novel insights and drug candidates.
• Specialized expertise in both artificial intelligence and biopharmaceutical development, combining two complex fields.

What Does BFRG Do?

Bullfrog AI Holdings, Inc., established in 2017 and headquartered in Gaithersburg, Maryland, functions as a digital biopharmaceutical company dedicated to transforming drug discovery and development through advanced artificial intelligence (AI) and machine learning (ML) technologies. The company's core offering is bfLEAP, a proprietary AI/ML platform engineered for the sophisticated analysis of complex preclinical and clinical data sets within the medicine and healthcare sectors across the United States. This platform is designed to identify patterns, predict outcomes, and accelerate the understanding of disease mechanisms and therapeutic efficacy, thereby aiming to streamline the traditionally lengthy and costly drug development process. Beyond its technological platform, Bullfrog AI Holdings, Inc. has strategically secured key intellectual property through licensing agreements with prominent academic institutions. One such agreement is with George Washington University, granting the company rights to utilize siRNA targeting Beta2-spectrin. This technology is being explored for its potential in treating a range of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), representing areas with significant unmet medical needs. Additionally, the company holds a licensing agreement with Johns Hopkins University for the application of a specific formulation of Mebendazole. This formulation is being investigated for its utility in the treatment of various human cancers or neoplastic diseases, indicating Bullfrog AI's commitment to addressing critical oncology challenges. With a lean operational structure supported by 4 employees, Bullfrog AI Holdings, Inc. positions itself at the intersection of biotechnology and artificial intelligence, seeking to innovate within the biopharmaceutical landscape by applying data-driven insights to therapeutic development.

What Products and Services Does BFRG Offer?

• Develops and operates bfLEAP, an artificial intelligence and machine learning (AI/ML) platform for analyzing medical and healthcare data.
• Focuses on applying AI/ML to preclinical and clinical data sets to accelerate drug discovery and development.
• Holds a licensing agreement with George Washington University for siRNA targeting Beta2-spectrin for diseases like hepatocellular carcinoma, obesity, NAFLD, and NASH.
• Possesses a licensing agreement with Johns Hopkins University for a Mebendazole formulation for the treatment of human cancers.
• Aims to identify patterns and insights from complex biological data to improve therapeutic outcomes.
• Operates as a digital biopharmaceutical company in the United States.

How Does BFRG Make Money?

• Monetizes its proprietary bfLEAP AI/ML platform through its application to internal drug development programs.
• Generates potential future revenue through milestone payments and royalties from its licensed therapeutic candidates if they advance through clinical trials and achieve commercialization.
• Potentially seeks partnerships and collaborations with larger pharmaceutical companies for platform utilization or co-development of drug assets.
• Focuses on intellectual property development and licensing to create long-term value.

What Industry Does BFRG Operate In?

Bullfrog AI Holdings, Inc. operates within the dynamic and rapidly evolving intersection of the healthcare and artificial intelligence sectors, specifically targeting medical and healthcare information services. The broader healthcare AI market is experiencing significant growth, driven by the increasing volume of complex biological and clinical data, the demand for accelerated drug discovery, and the need for more personalized medicine approaches. Bullfrog AI's bfLEAP platform positions it as a participant in this trend, offering a specialized tool for data analysis that aims to reduce R&D timelines and costs. The competitive landscape includes established pharmaceutical companies integrating AI, dedicated AI-driven drug discovery startups, and larger technology firms entering healthcare. Bullfrog AI differentiates itself through its specific licensing agreements for therapeutic candidates and its focused AI/ML platform, aiming to carve out a niche by directly addressing specific disease areas like hepatocellular carcinoma, NAFLD, NASH, obesity, and various cancers. Its small size and specialized focus allow for agility, but also necessitate strategic partnerships and successful clinical progression to compete effectively against larger, more resourced entities.

Who Are BFRG's Key Customers?

• Internal R&D teams leveraging the bfLEAP platform for drug discovery.
• Potential future pharmaceutical partners or licensees interested in the bfLEAP platform or specific therapeutic candidates.
• Ultimately, patients suffering from diseases targeted by its licensed therapies (e.g., hepatocellular carcinoma, obesity, NAFLD, NASH, various cancers).

Bullfrog AI Holdings, Inc. Common Stock (BFRG) Valuation Context

Valued at $9.00M, BFRG is classified as a micro-cap stock.

BFRG Revenue & Earnings Trend

In Jun 2026, BFRG generated $215K in top-line revenue. The company recorded a net loss of $1.4M, with diluted EPS of $-0.07. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BFRG averaged $-0.12 in diluted EPS.

Company Profile

Bullfrog AI Holdings, Inc. Common Stock operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Gaithersburg, US. The company is led by CEO Vininder Singh. BFRG has traded publicly since 2023.

Key Financial Metrics

Its free cash flow yield is -76.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -70.1%, the inverse of the P/E and a quick read on earnings relative to price.

Bullfrog AI Holdings, Inc. Common Stock's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.49 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Bullfrog AI Holdings, Inc. Common Stock revenue of about $780K for fiscal 2026, with EPS near $-0.37.

Over the past six months, Bullfrog AI Holdings, Inc. Common Stock insiders filed 3 SEC Form 4 transactions — 0 sales and 3 purchases. On net that is roughly 45K shares acquired (about $28K) — insiders putting money in tends to read as conviction.

BFRG Financials

BFRG Latest News

BFRG Analyst Consensus

BFRG MoonshotScore

Bullfrog AI Holdings, Inc. Common Stock Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources